Goldman Sachs analyst Umang Choudhary downgrades Comstock Res (NYSE:CRK) from Neutral to Sell.
Jefferies Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $50
Jefferies analyst Michael Yee initiates coverage on Immuneering (NASDAQ:IMRX) with a Buy rating and announces Price Target of $50.